US FDA audit timing uncertainty
Customer filings with US FDA will trigger audit requirements, but timing is entirely regulator-dependent and could extend into next year, delaying regulated market entry.
NGLFINE / Q4-FY26 / risks
Keep the risk register visible.
NGL Fine-Chem · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Forex loss quantification withheld
Analyst directly asked for forex mark-to-market loss quantification; management deflected, stating they don't have the number available, leaving margin impact unclear.
Chinese price competition in regulated markets
Chinese competitors did not raise prices during Q4 despite input cost increases, creating margin pressure that may persist in competitive segments, particularly in regulated market entry.
Return to pre-oversupply margin levels unlikely near-term
Management acknowledged that 20-21% EBITDA margins seen historically are unlikely to return for 2-3 years due to significant Chinese and Indian capacity expansion creating structural oversupply.